Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines

Welf PragerDermatologikum Hamburg, Hamburg, GermanyObjectives: This review examines the pharmacologic and clinical characteristics of incobotulinumtoxinA (Xeomin&reg;/Xeomeen&reg;/Bocouture&reg;/XEOMIN Cosmetic&trade;; botulinum toxin type A [150 kDa]), which is free...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Prager W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/5880265a31234a43a39317edae50b97a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5880265a31234a43a39317edae50b97a
record_format	dspace
spelling	oai:doaj.org-article:5880265a31234a43a39317edae50b97a2021-12-02T06:58:56ZDifferential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines1179-1438https://doaj.org/article/5880265a31234a43a39317edae50b97a2013-03-01T00:00:00Zhttp://www.dovepress.com/differential-characteristics-of-incobotulinumtoxina-and-its-use-in-the-a12444https://doaj.org/toc/1179-1438Welf PragerDermatologikum Hamburg, Hamburg, GermanyObjectives: This review examines the pharmacologic and clinical characteristics of incobotulinumtoxinA (Xeomin&reg;/Xeomeen&reg;/Bocouture&reg;/XEOMIN Cosmetic&trade;; botulinum toxin type A [150 kDa]), which is free from complexing proteins, and discusses its efficacy and safety in the treatment of glabellar frown lines. Differences between incobotulinumtoxinA and other commercially available botulinum neurotoxin type A (BoNT/A) products that have been approved by the European Medicines Agency, US Food and Drug Administration, and other regulatory agencies for this indication are also discussed.Findings: IncobotulinumtoxinA differs from other commercially available BoNT/A preparations, in that it is free from complexing proteins and contains only active neurotoxin, minimizing foreign protein load. IncobotulinumtoxinA is commonly used at a 1:1 dose ratio with onabotulinumtoxinA and displays comparable efficacy and safety; furthermore, it is associated with early onset and long duration of effect, and high levels of subject satisfaction. In terms of practical considerations, incobotulinumtoxinA does not require cold storage and demonstrates low spread, enabling precise treatment and good tolerability.Conclusion: IncobotulinumtoxinA is an efficacious and well-tolerated treatment for glabellar frown lines. It differs from other BoNT/A preparations, in that it is free from complexing proteins and contains only active neurotoxin, which is relevant clinically, as this reduces the foreign protein load and minimizes the risk of neutralizing antibody production. In practical terms, incobotulinumtoxinA has a long shelf-life, remaining stable without the need for refrigeration, and due to its limited spread is a precise localized treatment.Keywords: clinical use, glabellar frown lines, incobotulinumtoxinA, pharmacology, complexing proteinsPrager WDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss Issue 1, Pp 39-52 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Prager W Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
description	Welf PragerDermatologikum Hamburg, Hamburg, GermanyObjectives: This review examines the pharmacologic and clinical characteristics of incobotulinumtoxinA (Xeomin&reg;/Xeomeen&reg;/Bocouture&reg;/XEOMIN Cosmetic&trade;; botulinum toxin type A [150 kDa]), which is free from complexing proteins, and discusses its efficacy and safety in the treatment of glabellar frown lines. Differences between incobotulinumtoxinA and other commercially available botulinum neurotoxin type A (BoNT/A) products that have been approved by the European Medicines Agency, US Food and Drug Administration, and other regulatory agencies for this indication are also discussed.Findings: IncobotulinumtoxinA differs from other commercially available BoNT/A preparations, in that it is free from complexing proteins and contains only active neurotoxin, minimizing foreign protein load. IncobotulinumtoxinA is commonly used at a 1:1 dose ratio with onabotulinumtoxinA and displays comparable efficacy and safety; furthermore, it is associated with early onset and long duration of effect, and high levels of subject satisfaction. In terms of practical considerations, incobotulinumtoxinA does not require cold storage and demonstrates low spread, enabling precise treatment and good tolerability.Conclusion: IncobotulinumtoxinA is an efficacious and well-tolerated treatment for glabellar frown lines. It differs from other BoNT/A preparations, in that it is free from complexing proteins and contains only active neurotoxin, which is relevant clinically, as this reduces the foreign protein load and minimizes the risk of neutralizing antibody production. In practical terms, incobotulinumtoxinA has a long shelf-life, remaining stable without the need for refrigeration, and due to its limited spread is a precise localized treatment.Keywords: clinical use, glabellar frown lines, incobotulinumtoxinA, pharmacology, complexing proteins
format	article
author	Prager W
author_facet	Prager W
author_sort	Prager W
title	Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
title_short	Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
title_full	Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
title_fullStr	Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
title_full_unstemmed	Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
title_sort	differential characteristics of incobotulinumtoxina and its use in the management of glabellar frown lines
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/5880265a31234a43a39317edae50b97a
work_keys_str_mv	AT pragerw differentialcharacteristicsofincobotulinumtoxinaanditsuseinthemanagementofglabellarfrownlines
_version_	1718399631918891008

Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines

Ejemplares similares